TrialPath
Recruiting

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07562152 · Immuneering Corporation
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)
About this study
This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with atebimetinib plus a modified schedule of gemcitabine and nab-paclitaxel will improve overall survival compared with standard gemcitabine and nab-paclitaxel when given as first-line treatment in patients with metastatic pancreatic adenocarcinoma. Patients will be randomized to one of two arms: Arm A with atebimetinib + gemcitabine and nab-paclitaxel (modified dosing schedule) or Arm B with gemcitabine and nab-paclitaxel.
Eligibility criteria
Inclusion Criteria: * Must be ≥18 years of age * Must have confirmed diagnosis according to AJCC staging as follows: * Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Participants must be treatment naive as follows: * First-line PDAC participants will have received no previous systemic anti-cancer therapy * Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria * Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values Exclusion Criteria: * Inability to swallow oral medications * Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma * Participants with only locally advanced disease * Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases
Study design
Enrollment target: 570 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-06-05
Estimated completion: 2029-02
Last updated: 2026-11-06
Interventions
Drug: AtebimetinibDrug: GnPDrug: mGnP
Primary outcomes
  • • Overall Survival (Up to approximately 2 years)
Sponsor
Immuneering Corporation · industry
Contacts & investigators
ContactImmuneering Study Team · contact · clinicaltrials@immuneering.com · 860-321-1302
All locations (76)
Clearview Cancer InstituteRecruiting
Huntsville, Alabama, United States
City of HopeRecruiting
Phoenix, Arizona, United States
City of HopeRecruiting
Duarte, California, United States
University of California San DiegoRecruiting
San Diego, California, United States
Poudre Valley Health Care, IncRecruiting
Fort Collins, Colorado, United States
Rocky Mountain Cancer CentersRecruiting
Lone Tree, Colorado, United States
Medical Oncology Hematology ConsultantsRecruiting
Newark, Delaware, United States
Miami Cancer InstituteRecruiting
Miami, Florida, United States
Hematology Oncology Associates of the Treasure CoastRecruiting
Port Saint Lucie, Florida, United States
Florida Cancer Specialists - SouthRecruiting
Sarasota, Florida, United States
Florida Cancer Specialists - NorthRecruiting
St. Petersburg, Florida, United States
Florida Cancer Specialists - EastRecruiting
West Palm Beach, Florida, United States
Piedmont Cancer InstituteRecruiting
Atlanta, Georgia, United States
Piedmont HealthcareRecruiting
Atlanta, Georgia, United States
Illinois Cancer SpecialistsRecruiting
Arlington Heights, Illinois, United States
City of HopeRecruiting
Chicago, Illinois, United States
OSF Medical CenterRecruiting
Peoria, Illinois, United States
University of Kansas Cancer CenterRecruiting
Fairway, Kansas, United States
Maryland OncologyRecruiting
Columbia, Maryland, United States
Missouri Cancer AssociatesRecruiting
Columbia, Missouri, United States
University of Nebraska Medical CenterRecruiting
Omaha, Nebraska, United States
Comprehensive Cancer CentersRecruiting
Las Vegas, Nevada, United States
Regional Cancer CareRecruiting
Belleville, New Jersey, United States
Astera Cancer CareRecruiting
East Brunswick, New Jersey, United States
NYU Langone HealthRecruiting
New York, New York, United States
Memorial Sloan Kettering Cancer CenterRecruiting
New York, New York, United States
FirstHealth of the CarolinasRecruiting
Pinehurst, North Carolina, United States
University of Cincinnati Cancer CenterRecruiting
Cincinnati, Ohio, United States
Taylor Cancer Research CenterRecruiting
Maumee, Ohio, United States
Willamette Valley Cancer InstituteRecruiting
Eugene, Oregon, United States
Oregon Health and Science UniversityRecruiting
Portland, Oregon, United States
Thomas Jefferson UniversityRecruiting
Philadelphia, Pennsylvania, United States
Prisma HealthRecruiting
Greenville, South Carolina, United States
Avera Cancer Institute ResearchRecruiting
Sioux Falls, South Dakota, United States
West Cancer CenterRecruiting
Germantown, Tennessee, United States
Sarah Cannon Research InstituteRecruiting
Nashville, Tennessee, United States
Tennessee OncologyRecruiting
Nashville, Tennessee, United States
Texas Oncology - West TexasRecruiting
Abilene, Texas, United States
Texas Oncology - AustinRecruiting
Austin, Texas, United States
Texas Oncology - San AntonioRecruiting
San Antonio, Texas, United States
Texas Oncology Gulf CoastRecruiting
Webster, Texas, United States
Blue Ridge Cancer CareRecruiting
Blacksburg, Virginia, United States
Virginia Cancer SpecialistsRecruiting
Fairfax, Virginia, United States
Virginia Mason Medical CenterRecruiting
Seattle, Washington, United States
University of Washington Fred Hutchinson Cancer CenterRecruiting
Seattle, Washington, United States
Northwest Cancer SpecialistsRecruiting
Vancouver, Washington, United States
University of Wisconsin Carbone Cancer CenterRecruiting
Madison, Wisconsin, United States
Nepean Cancer Care CentreRecruiting
Kingswood, New South Wales, Australia
Calvary Mater NewcastleRecruiting
Waratah, New South Wales, Australia
GenesiscareRecruiting
Waratah, New South Wales, Australia
Icon Cancer Centre - ChermsideRecruiting
Chermside, Queensland, Australia
Princess Alexandra HospitalRecruiting
Woolloongabba, Queensland, Australia
Cancer Research South AustraliaRecruiting
Adelaide, South Australia, Australia
Bayside HealthRecruiting
Frankston East, Victoria, Australia
Fiona Stanley HospitalRecruiting
Murdoch, Western Australia, Australia
One Clinical ResearchRecruiting
Nedlands, Western Australia, Australia
Institute of Clinical OncologyRecruiting
Tbilisi, TB, Georgia
Caucasus Medical CentreRecruiting
Tbilisi, TB, Georgia
LTD "Multiprofile Clinic Consilium Medulla"Recruiting
Tbilisi, TB, Georgia
SLK-Kliniken Heilbronn GMBHRecruiting
Heilbronn, Baden-Wurttemberg, Germany
Elblandklinikum RiesaRecruiting
Riesa, Saxony, Germany
BKVMKRecruiting
Budapest, BD, Hungary
Pankreasz Betegsegek Intezete, Semmelweis UniversityRecruiting
Budapest, BU, Hungary
Orszagos Onkologiai IntezetRecruiting
Budapest, BU, Hungary
University of DebrecenRecruiting
Debrecen, Hungary
Pratia PoznanRecruiting
Poznan, Poland
Pratia S.A.Recruiting
Wroclaw, Poland
FutureMeds SRL - GalatiRecruiting
Galati, GL, Romania
SC Sigmedical S.R.LRecruiting
Suceava, Romania
Clinica Universidad de NavarraRecruiting
Pamplona, Spain
Instituto de Investigacion Sanitaria de Aragon (IIS-A)Recruiting
Zaragoza, Spain
University Hospitals Coventry and Warwickshire NHS TrustRecruiting
Coventry, COV, United Kingdom
University College London HospitalsRecruiting
London, LND, United Kingdom
Imperial College Healthcare NHSRecruiting
London, LND, United Kingdom
Scri Uk, LtdRecruiting
London, LND, United Kingdom
The Christie NHS FoundationRecruiting
Manchester, MAN, United Kingdom